Transfusie Op Maat (Patient Blood Management )
To investigate whether the use of alternatives to allogeneic blood for patients undergoing elective total knee or hip replacement surgery, e.g. the infusion of erythropoietin, the use of the cell-saver or the reinfusion of autologous wound drained blood, can lead to continuous sparing of allogeneic blood if a restrictive transfusion policy is used. The effect on post-operative complications, length of hospital stay, mobilization and rehabilitation, and the quality of life in relation to the estimated cost will also be investigated. *Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study.*
- Start Year
- End Year
- grant PPOC-03-002 from Sanquin Blood Supply (Amsterdam, The Netherlands) and by grant 06-601 from ZonMW (The Hague, The Nether-lands). In addition, Roche (Roche Nederland BV, Woerden, The Netherlands) and Haemonetics (Breda, The Nether-lands) provided grants for laboratory analyses (cytokine analyses) of wound blood (not reported in this study).
- Study design
- Clinical trial cohort
So-Osman C, Nelissen RG, Koopman-van Gemert AW, Kluyver E, Pöll RG, Onstenk R, Van Hilten JA, Jansen-Werkhoven TM, van den Hout WB, Brand R, Brand A. Patient blood management in elective total hip- and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology. 2014 Apr;120(4):839-51. doi: 10.1097/ALN.0000000000000134.
- Sources of Recruitment
Number of participants
- Number of participants
- Number of participants with biosamples
- Supplementary Information
- Orthopedic patients of 18 years and older being considered for a total knee replacement (TKR), total hip replacement (THR) or TKR/THR revision.
Availability of data and biosamples
No coverage data about the variables classifications are available.